Metabolite Profiling for Multiple Sclerosis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Multiple Sclerosis (MS) are inadequate, particularly in differentiating between disease phases and identifying effective treatment strategies, due to low sensitivity and subjective clinical outcomes, and a lack of accurate biomarkers for neurodegeneration and inflammation.
Innovation Solution
A method involving the determination of specific metabolite concentrations in blood and urine using high-resolution 1H-NMR spectroscopy and partial least squares discriminant analysis (PLS-DA) to diagnose MS and differentiate between its phases by identifying correlations between metabolite concentrations and the presence of MS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If metabolite profiling is used to diagnose MS, then diagnostic accuracy and ability to differentiate disease phases is improved, but complexity of the diagnostic method increases
Solution Approach 1:
The patent segments the complex diagnostic process into distinct metabolite measurements (blood metabolites, urine metabolites, CSF metabolites) that can be analyzed separately and then integrated. This segmentation allows the complex diagnostic challenge to be broken down into manageable analytical components, improving diagnostic accuracy while making the overall process more systematic and controllable
Solution Approach 2:
The patent introduces metabolite profiles as intermediary biomarkers that mediate between the complex pathological processes of MS and the diagnostic measurement. These metabolite profiles serve as intermediate indicators that translate complex disease states into measurable concentration patterns, thereby improving diagnostic precision without requiring direct measurement of complex disease mechanisms
2Ease of operation
If current clinical outcome measures are used, then ease of assessment is maintained, but sensitivity and pathogenic specificity deteriorate
Solution Approach 1:
The patent replaces subjective clinical assessment mechanisms with objective metabolite measurement mechanisms. Instead of relying on clinician and patient subjectivity in clinical scales, the invention substitutes metabolite concentration measurements that provide objective, quantifiable data with high sensitivity and pathogenic specificity, while maintaining ease of operation through standardized analytical procedures
3Reliability
If MRI is used to measure atrophy as a surrogate marker, then neuroprotection can be assessed, but sensitivity deteriorates in patients with severe or advanced disease
Solution Approach 1:
The patent changes the measurement parameter from structural atrophy (MRI-based) to metabolic parameters (metabolite concentrations). This parameter change allows for more sensitive detection of neuroprotection effects, as metabolite profiles can detect subtle metabolic changes before they manifest as structural atrophy, particularly in patients with severe or advanced disease where atrophy measurement becomes unreliable
4Ease of manufacture
If single metabolite detection methods are used, then simplicity of the assay is maintained, but predictive value at individual level deteriorates
Solution Approach 1:
The patent combines multiple metabolite measurements into a composite metabolite profile. This composite approach integrates information from various metabolites (blood, urine, CSF) to create a comprehensive diagnostic signature that has high predictive value at the individual level. The composite profile maintains assay simplicity through standardized measurement protocols while achieving superior diagnostic precision through the synergistic combination of multiple metabolite indicators
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a more accurate and individualized diagnosis of MS, enabling the differentiation between MS phases and potentially identifying new biomarkers for neuroprotective treatments, thereby improving treatment options and disease progression monitoring.
Implementation Method 1
determining the concentrations of two or more metabolites in a sample from said subject... Using a process of high resolution 1H-NMR (Nuclear Magnetic Resonance) spectroscopy
Data Source
AI summary
There is provided an in vitro method for diagnosing Multiple Sclerosis (MS) in a human test subject, comprising (i) determining the concentrations of two or more metabolites in a sample from said subject, wherein said two or more metabolites are selected from: blood metabolites, wherein said blood metabolites comprise: alanine, ascorbic acid, choline, fatty acid, glucose, lactate, N-acetyl aspartate, N-acetyl glycoprotein, n-butyrate, oxyglutaric acid, phosphocholine, taurinebetaine, tyrosine, L-glutamine, N-acetyl species, and beta-hydroxybutyrate; and/or urine metabolites, wherein said urine metabolites comprise: citrate, creatinine, inositol, lactate and trimethylamine N-oxide (TMAO); (ii) comparing the concentrations of said two or more metabolites in the sample with the concentrations of the same metabolites in at least one reference standard; and (iii) identifying a concentration difference for each of said two or more metabolites in the sample relative to the reference standard; wherein said concentration differences correlate with the presence of MS.